Traders should monitor prescription growth trends into Q2 2026 and assess whether VIZZ can scale to offset high commercialization costs. The expansion of the sales force to 117 territories and DTC campaign may drive uptake, but profitability remains distant.
Price Chart
Executive Summary
LENZ Therapeutics reported its first commercial revenue from VIZZ, generating $1.6 million in net product sales in Q4 2025, its initial quarter on the market after launch in October 2025. Despite strong early prescriber adoption and 45,000 paid prescriptions expected by Q1 2026, the company reported a significant net loss of $82.1 million for the year due to high SG&A expenses from the commercial launch. The sentiment is mixed due to promising product traction offset by substantial losses and negative operating margins.
Key Financial Metrics
Key Facts
- VIZZ generated $1.6 million in net product revenue in Q4 2025, its first full quarter on the market after launching in October 2025.
- Over 6,500 unique eye care professionals prescribed VIZZ in Q4 2025, with refill trends and adoption showing early momentum.
- SG&A expenses surged to $91.1 million in 2025 (from $28.8M in 2024) due to sales force buildout and pre-launch marketing.
- Net loss widened to $82.1 million in 2025 from $49.8 million in 2024, with full-year 2025 revenue at $19.1 million (mostly license revenue).
- Cash, cash equivalents, and marketable securities totaled $292.3 million as of December 31, 2025, funding operations into positive cash flow territory.
Financial Impact
$1.6 million in product revenue with $82.1 million net loss in 2025; $91.1 million spent on SG&A, indicating heavy investment ahead of scale.
Risk Factors
- High burn rate: SG&A expenses are nearly 5x product revenue, raising concerns about path to profitability.
- Product revenue is still minimal; long-term refill rates and patient retention are unproven.
- Forward-looking statements dominate; actual commercial success depends on sustained adoption beyond early adopters.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $3.25 | awaiting T+1 | — | $3.14 (−3.23%) |
Oct 21, 2026 5d ago | SC 13G/A | $3.25 $3.16 | ▼ −2.77% | ▼ −2.25% | $3.14 (−3.23%) |
Aug 11, 2026 10w ago | Press Release | $5.04 $4.60 | ▼ −8.73% | ▼ −9.43% | $3.14 (−37.60%) |
Jul 2, 2026 16w ago | 8-K | $5.89 $5.60 | ▼ −4.92% | ▼ −5.80% | $3.14 (−46.60%) |
Jun 11, 2026 19w ago | Institutional Cluster | $6.50 $6.77 | ▲ +4.15% | ▲ +3.61% | $3.14 (−51.62%) |
Jun 7, 2026 20w ago | Press Release | $6.72 $6.79 | ▲ +1.04% | ▲ +1.34% | $3.14 (−53.20%) |
May 11, 2026 24w ago | 8-K | $7.91 $7.91 | · 0.00% | ▼ −0.54% | $3.14 (−60.24%) |
May 4, 2026 25w ago | Press Release | $9.28 $9.07 | ▼ −2.26% | ▼ −3.06% | $3.14 (−66.11%) |
Mar 24, 2026 30w ago | Press Release | $9.03 $9.07 | ▲ +0.44% | ▼ −0.12% | $3.14 (−65.17%) |
Feb 28, 2026 34w ago | Institutional Cluster | $13.68 $13.15 | ▼ −3.87% | ▼ −2.96% | $3.14 (−77.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers